Acta Med. 2006, 49: 167-173
https://doi.org/10.14712/18059694.2017.127
IMRT with the Use of Simultaneous Integrated Boost in Treatment of Head and Neck Cancer: Acute Toxicity Evaluation
References
1. Int J Radiat Oncol Biol Phys 2003; 56:136–44.
< CM, Teh BS, Van TJ et al. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique. https://doi.org/10.1016/S0360-3016(03)00093-2>
2. Radiother Oncol 1998; 46:127–130.
< M, Bentzen SM, Ang KK. Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. https://doi.org/10.1016/S0167-8140(97)00173-4>
3. N Engl J Med 2004; 350:1945–52.
< J, Domenge C, Ozsahin M et al. European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. https://doi.org/10.1056/NEJMoa032641>
4. J Clin Oncol 2004; 22 (Suppl.): 5505.
< J, Amand C, Pignon JP, on behalf of the MACH-NC Collaborative Group. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy. https://doi.org/10.1200/jco.2004.22.14_suppl.5505>
5. Int J Radiat Oncol Biol Phys 2002; 54 (Suppl 1):71–72.
< J, Syz N, Overgaard J et al. Conventional vs modified fractionated radiotherapy, meta-analysis of radiotherapy in head & neck squamous cell carcinoma: a meta-analysis based on individual patient data abstract https://doi.org/10.1016/S0360-3016(02)03180-2>
6. J Clin Oncol 2005; 23:1125–35.
< V, Stuschke M, Budach W et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95–06 Prospective Randomized Trial. https://doi.org/10.1200/JCO.2005.07.010>
7. Radiother Oncol 2004; 73(Suppl.1): S71.
G. Late toxicity in patients treated with concurrent chemotherapy and radiotherapy for head and neck cancers
8. Int J Radiat Oncol Biol Phys 2001; 49:907–16.
< KS, Deasy JO, Markman J et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. https://doi.org/10.1016/S0360-3016(00)01441-3>
9. Head Neck 1998; 20:588–94.
< JS, Pajak TF, Forastiere A, et al. Precisely defining high-risk operable head and neck tumors based on RTOG #85–03 and #88–24: targets for postoperative radiochemotherapy? https://doi.org/10.1002/(SICI)1097-0347(199810)20:7<588::AID-HED2>3.0.CO;2-F>
10. Radiother Oncol 2004; 73 (Suppl. 1), S89.
WJM, Heijmen BJM,Voet P,van der Est H, Levendag PC. The importance of the low-dose part (D smaller than 95%) of the PTV-DVH in head and neck IMRT.
11. Int J Radiat Oncol Biol Phys 2003; 57:1480–91.
< N, King S, Emami B et al. Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing. https://doi.org/10.1016/S0360-3016(03)01569-4>
12. Int J Radiat Oncol Biol Phys 1999; 45:577–87.
< A, Ten Haken RK, Kim HM, Marsh LH, Ship JA. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity- modulated irradiation of head and neck cancer. https://doi.org/10.1016/S0360-3016(99)00247-3>
13. Radiother Oncol 2003; 69:161–168.
< JF, Harari PM, Leborgne F, Leborgne JH. Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. https://doi.org/10.1016/S0167-8140(03)00231-7>
14. Radiother Oncol 1997; 44:111–21.
< JC, Bontemps P, van den Bogaert W et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. https://doi.org/10.1016/S0167-8140(97)00079-0>
15. Int J Radiat Oncol Biol Phys 2004; 60: 374–87.
< A, Morris M, Schmidt-Ullrich R et al. Simultaneous integrated boost intensity- modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II—clinical results. https://doi.org/10.1016/j.ijrobp.2004.03.010>
16. Int J Radiat Oncol Biol Phys 2003; 57:49–60.
< N, Xia P, Fischbein NJ, Akazawa P, Akazawa C, Quivey JM. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. https://doi.org/10.1016/S0360-3016(03)00405-X>
17. Int J Radiat Oncol Biol Phys 2002; 53:12–22.
< N, Xia P, Quivey JM et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. https://doi.org/10.1016/S0360-3016(02)02724-4>
18. Int J Radiat Oncol Biol Phys 2003; 57:61–70.
< A, Kim HM, Terrell JE, Dawson LA, Ship JA, Eisbruch A. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. https://doi.org/10.1016/S0360-3016(03)00361-4>
19. Int J Radiat Oncol Biol Phys 2004; 58: 698–704.
< PD, Meyerson MB, Neal CR et al. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA headand- neck cancer in the community. https://doi.org/10.1016/S0360-3016(03)01576-1>
20. Int J Radiat Oncol Biol Phys 2000; 46:619–30.
< R, Wu Q, Manning M, Schmidt-Ullrich R. Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. https://doi.org/10.1016/S0360-3016(99)00438-1>
21. Med Phys 1999; 26:1100.
A. A generalized concept of equivalent uniform dose (abstract).
22. Lancet 2003; 362:933–40.
< J, Hansen HS, Specht L et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. https://doi.org/10.1016/S0140-6736(03)14361-9>
23. Lancet 2000; 355:949–955.
< JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. https://doi.org/10.1016/S0140-6736(00)90011-4>
24. Int J Radiat Oncol Biol Phys 2000; 47:1–12.
< A. Toxicity in head and neck cancer: a review of trends and issues. https://doi.org/10.1016/S0360-3016(99)00558-1>
25. Int J Radiat Oncol Biol Phys 2000; 48: 711–22.
< K, Shu HK, Xia P et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. https://doi.org/10.1016/S0360-3016(00)00702-1>
26. Int J Radiat Oncol Biol Phys 2000; 46:195–205.
< Q, Manning M, Schmidt-Ullrich R, Mohan R. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. https://doi.org/10.1016/S0360-3016(99)00304-1>
27. Int J Radiat Oncol Biol Phys 2005; 63:410–421.
< M, Dornfeld KJ, Buatti JM et al. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma – the University of Iowa experience. https://doi.org/10.1016/j.ijrobp.2005.02.025>
28. http://www.rtog.org/members/protocols/h0022/h0022.pdf.
29. http://www.rtog.org/members/protocols/0225/0225.pdf.